Guizhou Bailing Group Pharmaceutical (002424) Fundamentals 2026 — Revenue Analysis | SniperIQ
Guizhou Bailing Group Pharmaceutical (002424) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.2B, trading at ¥4.41 on the SHZ. This SniperIQ fundamentals page covers Guizhou Bailing Group Pharmaceutical's valuation, profitability (net margin -3.4%), revenue (¥3.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guizhou Bailing Group Pharmaceutical's market cap?
Guizhou Bailing Group Pharmaceutical (002424) has a market capitalization of approximately ¥6.2B, trading at ¥4.41 on the SHZ. Market cap moves with the live share price.
What is Guizhou Bailing Group Pharmaceutical's P/E ratio?
Guizhou Bailing Group Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guizhou Bailing Group Pharmaceutical?
Guizhou Bailing Group Pharmaceutical runs a net profit margin of -3.4%, a gross margin of 46.1%, and an operating margin of 2.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guizhou Bailing Group Pharmaceutical generate?
Guizhou Bailing Group Pharmaceutical reported revenue of ¥3.0B for fiscal year 2025, with net income of -¥104M and earnings per share (EPS) of -0.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guizhou Bailing Group Pharmaceutical pay a dividend?
Guizhou Bailing Group Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Guizhou Bailing Group Pharmaceutical financially healthy?
Guizhou Bailing Group Pharmaceutical carries a debt-to-equity ratio of 0.31x and a current ratio of 0.95x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guizhou Bailing Group Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guizhou Bailing Group Pharmaceutical (002424) the key facts are: market cap ¥6.2B, revenue ¥3.0B, 52-week range 4.08-6.94. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guizhou Bailing Group Pharmaceutical's full fundamentals live
Get Guizhou Bailing Group Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.